Condition: PreDiabetes · Sponsor: The University of Texas Health Science Center, Houston
This project uses both transcriptomic- and genomic-level data to identify mechanisms of individual responses to glucagon-like peptide-1 (GLP-1) in Mexican-Americans with prediabetes. The GLP-1 hormone is essential for glucose reduction, weight loss, cardiovascular risk reduction, and renal protection. Newly discovered mechanisms will illuminate causal links between disease genotype and phenotype, which may ultimately guide personalized therapeutic approaches for type 2 diabetes, prediabetes, obesity, cardiovascular disease, renal disease, and other related diseases.
This description comes directly from the study's public registry record.
Norma Perez-Olazaran · (956) 755-0695 · Norma.P.PerezOlazaran@uth.tmc.edu
Rocio Uribe · (956) 882-5165 · Rocio.D.Uribe@uth.tmc.edu
Always discuss trial participation with your own doctor first.
| UTHealth Clinical Research Unit (CRU) at UT Brownsville | Brownsville, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05119179